Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$3745.00
-65.00 (-1.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-3.5B · quality 44.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$155.2B
P/E
11.3x
↓EV/EBITDA
6.9x
↓ROE
5.7%
↑Gross Margin
49.9%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.5%
FCF CAGR
—
FCF margin
1.7%
FCF / Net income
0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $88.33B · net income $11.96B · FCF $1.49B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $88.33B | $88.33B | $75.58B | $67.49B | $65.38B |
| Net Income | $11.96B | $11.96B | $11.16B | $10.53B | $12.92B |
| EBITDA | $20.25B | $20.25B | $18.72B | $17.81B | $20.26B |
| EPS | 274.21 | 274.21 | 246.61 | 228.31 | — |
| Gross Margin | 49.9% | 49.9% | 49.4% | 48.0% | 47.8% |
| Operating Margin | 6.5% | 6.5% | 5.3% | -1.7% | -2.1% |
| Net Margin | 13.5% | 13.5% | 14.8% | 15.6% | 19.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 5.30 | 5.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.49B | $1.49B | $-3.51B | $-9.23B | $-386.0M |
| Returns | |||||
| ROE | 5.7% | 5.7% | 5.1% | 5.4% | 6.4% |
| Valuation | |||||
| P/E | 11.30 | 11.30 | 13.83 | 11.44 | — |
| EV/EBITDA | 6.89 | 6.89 | 7.09 | 5.39 | 4.26 |
| P/B | 0.78 | 0.78 | 0.70 | 0.62 | 0.57 |
| Growth & Yield | |||||
| Revenue Growth | 16.9% | 16.9% | 12.0% | 3.2% | — |
| EPS Growth | 11.2% | 11.2% | 8.0% | — | — |
| Dividend Yield | 3.4% | 3.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
6.6%
EPS terminal req.
$332.31
Spread vs growth
4.6%
5Y implied EPS CAGR
8.0%
EPS terminal req.
$402.09
Spread vs growth
3.2%
10Y implied EPS CAGR
9.0%
EPS terminal req.
$647.57
Spread vs growth
2.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.3%
Start / end P/E
15.8x → 13.7x
EPS bridge
246.61 → 274.21
Residual
-1.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.